

## Special Issue

# Advance in Genetic Research of Epilepsy

### Message from the Guest Editor

Over the last two decades, the landscape of epilepsy genetics has increasingly grown thanks to the availability of advanced genetic testing. Many new genes have been linked to various types of epilepsy and especially developmental and epileptic encephalopathies (DEE). In addition, epilepsy has been linked with microCNVs defining specific syndromic conditions. Furthermore, although rarely, epilepsy has been linked to non-coding repeated expansion. These genetic discoveries have improved our understanding of the molecular and cellular pathways involved in epilepsy, transforming our clinical practice. The most exciting implication is the possibility to provide new targets for the development of precision. This Special Issue will cover the following research topics:

- Current use of genetic testing in clinical and research settings;
- Developmental and epileptic encephalopathies-associated genes;
- CNVs-associated epilepsies;
- Repeated expansion disorders and epilepsy.

### Guest Editor

Dr. Antonietta Coppola

Department of Neuroscience, Odontostomatology and Reproductive Sciences, University of Naples Federico II, Naples, Italy

### Deadline for manuscript submissions

closed (31 January 2024)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/164485](https://mdpi.com/si/164485)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).